Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...
Lonza AG enters R&D collaboration with NeuroSense Therapeutics Ltd
Under the agreement with Lonza AG, NeuroSense Therapeutics Ltd will advance early diagnosis and treatment in the neurodegeneration field. Last...
AmphiStar BV secures €6m to expand production
The infusion of €6m in new capital from ECBF, Qbic III and FFTF will empower AmphiStar to kickstart commercial biosurfactant production in...
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Under the agreement, Skyhawk will provide its discovery platform for RNA-targeting small molecules across several therapeutic areas, including rare...
AZmed closes €15m Series A financing
AZmed said it will use the €15m to boost marketing of its proprietary artificial intelligence (AI) platform Rayvolve worldwide particularly in...
PulseSight to disrupt AMD space
Aiming to address the pressing challenges of age-related macular diseases (AMD), including wet and dry AMD, along with geographic atrophy (GA),...
Essential Pharma acquires Renaissance Pharma Ltd
Renaissance Pharma Ltd, which was only founded in September 2023 with the licensing of the anti-GD2 antibody from St Jude Children's Research...